Assessing the Clinical Abuse Potential of Abuse Deterrent Opioid Formulations
|
|
- Bertina Haynes
- 6 years ago
- Views:
Transcription
1 Assessing the Clinical Abuse Potential of Abuse Deterrent Opioid Formulations November 16, 2016 Beatrice Setnik, PhD VP, Clinical Pharmacology, Early Phase INC Research
2 Disclosure I am an employee of INC Research, and in this role I consult with various pharmaceutical and biotech companies.
3 Prescription Opioid Abuse Epidemic In 2014, an estimated 4.3 million people ( 12 years of age) were current nonmedical users of pain relievers in the US. 1 In 2015, an estimated 3.8 million people ( 12 years of age) were current misusers of pain relievers in the US. 2 There has been a shift in the demographic of opioid users over the last few decades. In the 1960s, more than 80% of people who began using opioids initiated with heroin. In the 2000s, 75% of opioid users reported that their first regular opioid was a prescription pain reliever Center for Behavioral Health Statistics and Quality. (2015). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA , NSDUH Series H-50). Retrieved from 2. Center for Behavioral Health Statistics and Quality. (2016). Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA , NSDUH Series H-51). Retrieved from 3. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry Jul 1;71(7):821-6.
4 Abuse Deterrent Opioids One of many tools to mitigate opioid abuse/misuse Formulations that deter abuse may be useful in ensuring access to drugs for purposes of medical treatment while limiting abuse and the consequences of abuse 1 Introduce some impediments to abuse, as opposed to the outright elimination of abuse 1. Guidance for Industry. Assessment of Abuse Potential of Drugs. US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). January 2010.
5 Types of Tampering & Abuse Prescription drugs can be abused by swallowing whole or the product can be tampered with (e.g., crushing) for abuse by swallowing, snorting, dissolving in solution and injecting, or smoking. Swallowing Whole Tampered Product Snorting Injecting Smoking
6 Types of Abuse Deterrent Formulations Technologies include: Physical/chemical barriers to tampering Agonist/antagonist combinations Aversion - substances combined to produce unpleasant effects if manipulated/administered at high doses Delivery system - e.g., depot injectable formulations and implants New molecular entities and prodrug - lacks activity until transformed in GI tract Combination - two or more of the above methods Novel approaches - this category encompasses novel approaches or technologies that are not captured in the previous categories Guidance for Industry. Abuse-Deterrent Opioids- Evaluation and Labeling. US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). April 2015.
7 Progression of Abuse AD technologies should consider how a particular product is abused. Opioids can be abused by: increasing oral dose crushing/chewing + swallowing crushing + snorting Often there is a progression of abuse crushing + smoking crushing + dissolving + injecting
8 Regulatory Guidances
9 When Is Abuse Potential Assessed? An abuse potential assessment is conducted for new drugs, including new molecular entities, when the drug: Affects the central nervous system (CNS), Is chemically or pharmacologically similar to other drugs with known abuse potential, Produces psychoactive effects e.g., sedation, euphoria, mood changes, or Is a new formulation designed with a possible claim of abuse deterrent qualities An abuse potential assessment may also be necessary for a marketed product that: Presents an unexpected adverse event profile that includes events related to abuse potential, or Is being re-evaluated for a new route of administration that could affect its abuse potential
10 Abuse Deterrence Evaluation and Labeling Based on 4 categories of evidence
11 In Vitro (Category 1) In vitro (laboratory manipulation and extraction) studies determine likelihood of: Defeating or compromising a controlled-release mechanism Preparing an immediate-release formulation for alternative routes of administration Separating the aversive/antagonist ingredients from the opioid
12 Manipulation Evaluation to Support Clinical Studies In vitro data is critical to inform manipulation techniques for clinical studies Equipment for manipulation (e.g., mortar pestle, coffee grinder, grater) Duration of grinding/manipulation time Particle size distribution Appearance of ground powder (blinding) Identification of appropriate placebo and comparator Number of capsules/tablets per grind % recovery Stability and storage of ground material
13 Pharmacokinetic Studies (Category 2) Evaluate the in vivo properties of the formulation by comparing PK profiles of manipulated vs. intact formulation through one or more routes of administration. Routes should be relevant to drug and safe to administer Manipulation techniques guided by in vitro data - resulting in greatest release Consider what claims will be made (chewing crushing) Assessment of food/alcohol should be included When food is expected to increase exposure, subsequent abuse potential studies by the oral route should be conducted in the fed state Typically conducted in healthy volunteers; adverse events and tolerability assessed Special attention should be given to: Guidance for Industry. Abuse-Deterrent Opioids- Evaluation and Labeling. US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). January 2013.
14 FDA Guidance: Pharmacokinetic Studies (Category 2) Study Types Pharmacokinetic profile for the oral route of administration should be studied Chewed or crushed Healthy volunteers as long as naltrexone is used to block the pharmacodynamic effects of the opioids Intranasal pharmacokinetic profile may be important to assess (product dependent) Should be done in subjects experienced with intranasal opioid Need to consider the risks of the excipients in the product and if IN administration is justified Collect adverse events related to tolerability Intravenous Food and alcohol effects if such an effect is expected Assess if food effect is result of API or excipients Human abuse potential study may need to be done in fed state if food increases release Best to do in separate study and prior to Category 3 study if it may be a concern
15 FDA Guidance: Clinical Planning Results from PK studies can influence HAP studies e.g., if the extended-release characteristics of an AD opioid formulation cannot be defeated and PK profile remains unchanged following oral or nasal administration of the manipulated product, oral and nasal HAP studies may not be necessary Note that, for some development programs, it may be preferable to combine measures of pharmacokinetic parameters for Category 3 studies, in which case separate Category 2 studies may not be necessary. For the approved ADFs so far, this has been the preferred route
16 Clinical Abuse Potential Studies (Category 3) For drugs with abuse-deterrent properties, the purpose of a clinical abuse potential study is to assess the impact of the potentially abuse-deterrent formulation on measures that predict how probable it is that the formulation will be attractive to abusers ( liked ). Preferred design is a randomized, double-blind, placebo-controlled, and positive comparator-controlled crossover study. Generally conducted in a drug-experienced abuse population that is further selected using a pre-qualification phase (enrichment strategy). Various pharmacodynamic, pharmacokinetic, and safety measures implemented to assess subjective drug effects and exposure. Guidance for Industry. Abuse-Deterrent Opioids- Evaluation and Labeling. US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). January 2013.
17 How Is a Human Abuse Potential Study Conducted? These studies are typically conducted as single dose studies that are blinded (identity of drug is masked) The studies are usually crossover designs, in that each subject receives all treatments in a random order Typically, the study drug is compared to a placebo and a comparator that is usually the same opioid (immediate- or extended-release) The routes of administration can vary and can include both intended (as directed for therapy) and unintended routes used for the purpose of abuse (e.g., snorting, injection) Doses are chosen based on past experience with specific opioids in the study population Assessments are conducted during the time course of the drug s effects Guidance for Industry. Assessment of Abuse Potential of Drugs. US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). January 2010.
18 What Type of Subjects are Selected for Human Abuse Potential Studies? The study subjects are: Experienced, recreational drug users who have recent or current history of using the drug in the same class as the test drug (e.g., opioids, amphetamines) Healthy males and females (18 years or older) No current/prior addictive disorder and are non-dependent on the drug of abuse Non-dependence can be confirmed by using Diagnostics and Statistical Manual (DSM-IVR) criteria Pharmacological challenge (e.g., naloxone to precipitate withdrawal in opioiddependent individuals) Past recreational drug use experience is confirmed by: Subject reported history Pharmacological challenge (e.g., subject s ability to tell the difference between the effects of a comparator (abuse drug) vs. placebo) Guidance for Industry. Assessment of Abuse Potential of Drugs. US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). January Guidance for Industry. Abuse-Deterrent Opioids- Evaluation and Labeling. US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). January 2013.
19 What Is Measured in a Human Abuse Potential Study? Visual Analog Scales (VAS) are commonly used to assess subjective drug effects VAS for drug liking should be the primary measure, appears to correlate most directly with potential for abuse Other measures of particular interest include: Assessment of overall drug liking Assessment of high Assessment of likelihood to take the drug again Measure can be assessed using either a unipolar or bipolar scale, and a rational should be provided for the choice of a particular scale Training subjects on pharmacodynamic measures is critical in ensuring comprehension and appropriate subject selection Guidance for Industry. Abuse-Deterrent Opioids- Evaluation and Labeling. US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). January 2013.
20 Measuring Drug Effects Ratings of drug liking and other subjective effects are measured on Visual Analog Scales (0-100 point scale) Figure. Presentation of bipolar VAS Drug Liking scales
21 Additional Measures in Human Abuse Potential Studies Guidance For Industry: Assessment of Abuse Potential of Drugs (Draft Guidance). U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. January 2010.
22 Examples of Relative Reductions in Drug Liking for Two Test Drugs Compared to a Positive Comparator and Placebo Time course data presented on a bipolar 100 mm Visual Analog Scale for Drug Liking where 0 is Strong Disliking, 50 is neutral, and 100 is Strong Liking. Strong Drug Liking Placebo Positive Comparator Test Drug A Test Drug B Neutral Strong Drug Disliking Time
23 How Is Human Abuse Potential Data Interpreted? Primary analysis is typically the difference in means of the peak effects (E max ) 1 Take Drug Again considered a key secondary endpoint Consider pattern of findings across all of the measures Examine profile of subjective effects produced in terms of onset, peak duration of activity, and offset Qualitative aspects of the findings should be considered e.g., steepness of the drug liking response, duration of the liking effects, positive vs. negative effects What is clinically meaningful? Some studies suggest that a 10 point difference may be clinically meaningful 2,3 A recent study demonstrated that Overall Drug Liking was significantly associated with reduced real-world nonmedical use, healthcare utilization, and costs 4 1. Guidance For Industry: Assessment of Abuse Potential of Drugs (Draft Guidance). U.S. Department of Health and Human Services. Food an d Drug Administration. Center for Drug Evaluation and Research. January Eaton TA, Comer SD, Revicki DA, et al. Determining the clinically important difference in visual analog scale scores in abuse liability studies evaluating novel opioid formulations. Qual Life Res. 2012;21(6): Schoedel K, Shram M, Levy-Cooperman N, et al. Defining clinically important differences in subjective abuse potential measures. Presented: 74th Annual Meeting of the College on Problems of Drug Dependence, Palm Springs, CA, White AG, LeCates J, Birnbaum HG, et al. Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abusedeterrent opioids on rates of nonmedical use and associated healthcare costs. J Opioid Manage. 2015;11(3):
24 Summary Evaluation of abuse deterrent opioids requires careful consideration of the intended routes and tampering methods that are meant to be mitigated Pre-marketing claims can be supported by Category 1-3 studies which include in vitro (laboratory), pharmacokinetic, and human abuse potential studies Studies are surrogates for determining the attractiveness or abuse potential of an abuse deterrent formulation, under conditions of study Study limitations must be carefully considered
25 Thank you
26 Questions For more information on Abuse Potential evaluation, please contact: Beatrice Setnik, PhD VP Clinical Pharmacology, Early Phase INC Research 3201 Beechleaf Court, Suite 600, Raleigh, NC, USA, Tel: Cell:
FDA Briefing Document
FDA Briefing Document Joint Meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee September 11, 2015 Page 1 DISCLAIMER STATEMENT The
More informationIdentifying Key Characteristics and Habits of the Recreational Drug User
Identifying Key Characteristics and Habits of the Recreational Drug User Beatrice Setnik, PhD VP Scientific & Medical Affairs, Early Phase CBI Abuse Deterrent Formulations Summit Alexandria, VA March 7,
More informationIn Vitro Considerations for Development Abuse Deterrent Dosage Forms
In Vitro Considerations for Development Abuse Deterrent Dosage Forms Presentation to AAPS Annual Meeting Nov 3, 2014 Nagesh Bandi, Ph.D. Global CMC New Products Pfizer Inc. 1 Disclaimer The thoughts and
More informationDocuments Regarding Drug Abuse Assessments
Overview of the FDA Guidance Documents Regarding Drug Abuse Assessments ABUSE DETERRENT FORMULATION SCIENCE MEETING DISCUSSION OF THE FDA DRAFT GUIDANCE FOR INDUSTRY: ABUSE DETERRENT OPIOIDS EVALUATION
More informationPK/PD analysis in assessment of abuse deterrence
PK/PD analysis in assessment of abuse deterrence Megan J. Shram, PhD Director and Principal, Altreos Research Partners Inc. Adjunct Professor and Lecturer, Department of Pharmacology, University of Toronto
More information25/03/2014. Workshop Overview. Hot Topics in FDA Regulations and Pharmacotherapy Research that Impact Patient Care:
Hot Topics in FDA Regulations and Pharmacotherapy Research that Impact Patient Care: Sharon L. Walsh, Ph.D. Shanna Babalonis, Ph.D. Michelle Lofwall, M.D. Center on Drug and Alcohol Research Department
More informationFDA Briefing Document
FDA Briefing Document Joint Meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee September 10 2015 Page 1 DISCLAIMER STATEMENT The
More informationSetting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time?
Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time? Lewis S. Nelson, MD New York University School of Medicine New York City Poison Control Center Opioid Abuse Liability
More informationAbuse liability workshop. February 19, 2013
Abuse liability workshop February 19, 2013 Agenda Topic Presenter Duration Dinner 30 min Introduction Marta Sokolowska, PhD 5 min FDA Draft Guidance on Assessment of Abuse Potential of Drugs review of
More informationThe Evolution of Abuse Deterrent Drug Formulations: Testing Effectiveness from the Benchtop to the Real World
The Evolution of Abuse Deterrent Drug Formulations: Testing Effectiveness from the Benchtop to the Real World Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Executive Director,
More informationReference ID: NDA was approved on December 12, The product was not formulated with properties to deter abuse,
tablets (NDA 020553). 1 According to Purdue, the reformulated OxyContin (OCR) had controlled-release features that would be less easily compromised by tampering than the original OxyContin (OC), and thereby
More informationPrescription Opioid Abuse: Abuse-Deterrent Opioids as Part of a Multipronged Approach. For Pfizer Use Only
Prescription Opioid Abuse: Abuse-Deterrent Opioids as Part of a Multipronged Approach Table of Contents Chronic Pain and Prescription Opioids Source of Prescription Opioids and Patient Risk Assessment
More informationA LOOK AT ABUSE-DETERRENT OPIOIDS
JULY 2017 Drugs Under Review ICER s report reviewed evidence on ten abuse-deterrent formulations (ADF) of opioids. Nine of the drugs were extended release (ER) opioids, and one was immediate release (IR).
More information6/6/2017. The Role of ADFs in Curbing Opioid Abuse Can ADFs Reduce Opioid Abuse? 12-Month Financial Disclosures* Objectives
The Role of ADFs in Curbing Opioid Abuse Can ADFs Reduce Opioid Abuse? Lynn R. Webster, M.D. Vice President of Scientific Affairs PRA Health Sciences Salt Lake City, UT LRWebsterMD@gmail.com (801) 892-5140
More informationAbuse of opioid painkillers in the US is a major problem
As appeared in January 2018 Tablets & Capsules www.tabletscapsules.com formulation Abuse-deterrent formulation technologies: Opportunities and limitations Alyn McNaughton Lonza Too many Americans are misusing
More informationEvaluating Abuse, Misuse, Diversion, Overdose, Addiction, and Death in the Patient Population
Evaluating Abuse, Misuse, Diversion, Overdose, Addiction, and Death in the Patient Population ISCTM February 18, 2014 Beatrice Setnik, Ph.D. INC Research, Raleigh, NC Overview Prevalence of Rx drug misuse,
More informationRAPID Analysis of Routes of Administration: Oral to Non-Oral Transitions
RAPID Analysis of Routes of Administration: Oral to Non-Oral Transitions Dr. Theodore J. Cicero, PhD John P. Feighner Professor of Psychiatry Washington University in St. Louis, MO RAPID Program Overview
More informationOpioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities
1 National Academy of Medicine Session 4 Opioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center
More informationA National Perspective on the Abuse and Diversion of Prescription Drugs
A National Perspective on the Abuse and Diversion of Prescription Drugs Hilary L. Surratt, Ph.D Steven P. Kurtz, Ph.D. ARSH: Center for Applied Research on Substance Use and Health Disparities Faculty
More informationGOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE
POSITION PAPER GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE Governments across Canada are concerned about the abuse of prescription drugs, with recent policy discussions focused on mitigating
More informationCategory 4 Can we prove that ADF opioids really are?
Human Abuse Liability & Abuse-Deterrent Formulations Category 4 Can we prove that ADF opioids really are? March 7, 2016 Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Executive
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationT E C H N O L O G Y INTRODUCTION F I G U R E 1 F I G U R E 2
ABUSE DETERRENT T E C H N O L O G Y New Abuse Deterrent Formulation (ADF) Technology for Immediate-Release Opioids By: Johannes Bartholomäus, PhD; Sebastian Schwier, PhD; Martin Brett, Hans-Jürgen Stahlberg,
More informationAbuse-Deterrent Formulations
Abuse-Deterrent Balancing Evidence with Value Tyson Thompson, PharmD Clinical Consultant Pharmacist University of Massachusetts Medical School Clinical Pharmacy Services Disclosure Statement I have no
More informationDo Pre Marketing Studies Anticipate Post Market Consequences? A Case Study of Reformulated Oxycontin
Do Pre Marketing Studies Anticipate Post Market Consequences? A Case Study of Reformulated Oxycontin Edward M. Sellers MD, PhD, FRCPC, FACP Professor Emeritus, University of Toronto Principal, DL Global
More informationDan Cohen Forum Chair - Abuse DeterrentCoalition. Abuse Deterrent Formulations of Opioids and the Abuse Deterrent Coalition
Dan Cohen Forum Chair - Abuse DeterrentCoalition Abuse Deterrent Formulations of Opioids and the Abuse Deterrent Coalition Prescription Drug Abuse and Diversion Partnering with Law Enforcement, Anti-Drug
More informationEffect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids
Effect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids Richard C. Dart, MD, PhD Executive Director, RADARS System Professor, University of Colorado Competing
More informationAvailable for Public Release
FDA ADVISORY COMMITTEE BRIEFING DOCUMENT Xtampza ER (EXTENDED-RELEASE OXYCODONE) JOINT MEETING OF THE ANESTHETIC AND ANALGESIC DRUG PRODUCTS ADVISORY COMMITTEE AND THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY
More informationHow to inject op oxycontin
How to inject op oxycontin The Borg System is 100 % How to inject op oxycontin Injecting oxycontin is one of the primary methods of abusing this highly addictive prescription drug. Injecting oxycontin
More informationBACKGROUND PAPER FOR FDA GUIDANCE DOCUMENT
I. INTRODUCTION BACKGROUND PAPER FOR FDA GUIDANCE DOCUMENT This document provides background and structure for the FDA to support development of a Guidance Document to industry on the development of abuse-deterrent
More informationOpioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective
Opioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective February 13, 2018 Frank Vocci, PhD New Therapies on the Horizon The planners, editors, faculty and reviewers of this activity
More informationValue of Abuse-Deterrent Opioids. For your personal use. Not for further distribution.
Value of Abuse-Deterrent Opioids HHS Data Show that Prescription Opioid Abuse Continues To Be a Serious Public Health Issue At least half of all opioid overdose deaths in the United States (US) involve
More informationThe Challenge of Treating Pain
FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and
More informationGuidance for Industry
Guidance for Industry Assessment of Abuse Potential of Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationAbuse-Deterrent Formulations of Opioids: Effectiveness and Value
Abuse-Deterrent Formulations of Opioids: Effectiveness and Value Evidence Report June 28, 2017 Prepared for: Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants Reiner Banken, MD, MSc
More informationAs part of the Opioid Analgesic REMS, all opioid analgesic companies must provide the following:
Introduction FDA s Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain (January 2018) Background In July 2012, FDA approved
More informationUnderstanding the US Opioid Analgesic Market
Understanding the US Opioid Analgesic Market Key Trends & Market Snapshot December 2017 Purdue Pharma L.P. provided funding and content review for this report. Avalere Health maintained full editorial
More informationInvestors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD
Investors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD February 7, 2017 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationPost-Marketing Surveillance: Lessons Learned and Recommendations for the Future
+ Post-Marketing Surveillance: Lessons Learned and Recommendations for the Future Dr. Theodore J. Cicero, PhD Washington University in St. Louis, Department of Psychiatry + Conflicts of Interest/Disclosure
More informationCorporate Presentation (Nasdaq: COLL) June 1, 2015
Corporate Presentation (Nasdaq: COLL) June 1, 2015 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationSafety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America
Safety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America Agenda Introduction GI presentation rescheduled Upcoming SPS
More informationEpidemiologic Data on Opioid Use: Changing Problems
Epidemiologic Data on Opioid Use: Changing Problems 1 Goals 1 To bridge the pain world and addiction world 1. Pain and pain treatment a. Chronic pain affects an estimated 100 million Americans (1/3 of
More informationPrescription Drug Abuse: Prevention and Treatment Across the Continuum of Care
Prescription Drug Abuse: Prevention and Treatment Across the Continuum of Care Scott P. Novak, Ph.D. Senior Research Scientist RTI International RTI International is a trade name of Research Triangle Institute.
More informationChallenges in Conducting Postmarketing Abuse Investigations
Challenges in Conducting Postmarketing Abuse Investigations Paul Coplan, ScD, MBA Risk Management & Epidemiology Purdue Pharma, L.P. ADF Guidance Meeting Washington DC, October 1, 2013 1 That which we
More informationPRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE
PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE September 20, 2013 Association of State and Territorial Health Officials Annual Meeting R. Gil Kerlikowske Director of National Drug Control Policy National
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationPURDUE PHARMA L.P. NDA Avridi (Immediate-Release Oxycodone Hydrochloride) Tablets
PURDUE PHARMA L.P. NDA 206830 Avridi (Immediate-Release Oxycodone Hydrochloride) Tablets Advisory Committee Briefing Materials For Joint Meeting of the Drug Safety and Risk Management Advisory Committee
More informationLessons Learned from the US Prescription Opioid Abuse Epidemic
Lessons Learned from the US Prescription Opioid Abuse Epidemic Michelle Lofwall, M.D. University of KY, Dept. of Psychiatry Center on Drug and Alcohol Research October 3, 2012 Outline for today s talk
More informationCase Study. Bill a patient with chronic low back pain. 45 years old Divorced, father of two children ages 11 and 16.
Case Study Bill a patient with chronic low back pain Demographics: 45 years old Divorced, father of two children ages 11 and 16. Shares joint custody with his ex-wife and has the children every other weekend
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More informationOxycodone DETERx : A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain
Pain Ther (2016) 5:171 186 DOI 10.1007/s40122-016-0062-1 REVIEW Oxycodone DETERx : A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain Jeff Gudin
More informationAligning Market Objectives and Policy for National Public Health
Abuse-Deterrent Formulations Summit March 7, 2017 Alexandria, Virginia Aligning Market Objectives and Policy for National Public Health Shruti Kulkarni, Esq. Outside Counsel Twitter: @claad_coalition CLAAD
More informationOXYCONTIN Diversion & Abuse Drug Enforcement Administration Office of Diversion Control October 2003
OXYCONTIN Diversion & Abuse Office of Diversion Control October 2003 OXYCONTIN OxyContin is a controlled release form of Schedule II oxycodone Manufactured in tablet form and intended for oral ingestion
More informationPrescription Opioids and Heroin
National Institute on Drug Abuse (NIDA) Prescription Opioids and Heroin Last Updated January 2018 https://www.drugabuse.gov 1 Table of Contents Prescription Opioids and Heroin Introduction Prescription
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release Oxycodone/Acetaminophen Tablets (CR OC/APAP) in an Acute Pain Model Neil
More informationClinical Trial Results Summary Study EN
Study Number: EN3288-113 Title of Study: A Double-blind, Dose-Ranging, Pilot Study to Evaluate the Safety, Subjective Effects, and Pharmacokinetics of Oxymorphone Hydrochloride in Healthy Subjects Who
More informationOverdoses of pain medications and heroin rise dramatically in the Finger Lakes
Issue Brief Overdoses of pain medications and heroin rise dramatically in the Finger Lakes As the Centers for Disease Control and Prevention (CDC) and the U.S. Department of Health and Human Services have
More informationOpioid Analgesics: Responsible Prescribing in the Midst of an Epidemic
Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic Lucas Buffaloe, MD Associate Professor of Clinical Family and Community Medicine University of Missouri Health Care Goals for today
More informationMEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER
MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER JOHN E LOPES Jr., DHSC, PA-C Associate Professor, Physician Assistant Program Central Michigan University and Project Director Medication-assisted
More informationEvolution of the Opioid Epidemic
Clinical Directors Network, Inc. (CDN) Evolution of the Opioid Epidemic February 5, 2018 2:30 PM-4:00 PM EST Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center, Denver Health Professor,
More informationRetrospective analyses of abuse-related outcomes in clinical trials of analgesic drugs and their interpretation
Retrospective analyses of abuse-related outcomes in clinical trials of analgesic drugs and their interpretation IMMPACT-X Abuse Deterrent Opioid Analgesics June 2-4, 2009 Arlington, Virginia USA Michael
More informationTHE PRESCRIPTION OPIOID EPIDEMIC: IN SEARCH OF MISSION CONTROL. G. Caleb Alexander, MD, MS November 11, 2014
THE PRESCRIPTION OPIOID EPIDEMIC: IN SEARCH OF MISSION CONTROL G. Caleb Alexander, MD, MS November 11, 2014 Disclosures and Funding Disclosures Consultant: IMS Health Chair, Food and Drug Administration,
More informationPress Release PP-US-MB /17
Press Release Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce U.S. Availability of MorphaBond ER (morphine sulfate) Extended-Release Tablets CII, an Abuse-Deterrent Formulation Basking
More informationRelapsing Late in Life: Opioid use disorder in a geriatric patient
Relapsing Late in Life: Opioid use disorder in a geriatric patient Kerry Sheets, MD Geriatric Medicine Fellow, HCMC MAGIC Annual Conference, 11/9/2018 Outline Case presentation Epidemiology of opioid use/misuse
More informationRunning Head: PICOT-D ASSIGNMENT 1. NURS 610: PICOT-D Assignment. Peggie L. Powell. VCU School of Nursing DNP Program
Running Head: PICOT-D ASSIGNMENT 1 NURS 610: PICOT-D Assignment Peggie L. Powell VCU School of Nursing DNP Program PICOT-D ASSIGNMENT 2 PICOT-D Component Component Wording (P)atient population Among providers
More informationWhat is pregabalin? Pregabalin tablets. Pregabalin misuse. National Drug Treatment Centre Research. Administration
What is pregabalin? Pregabalin is a prescription drug used to manage a number of long-term conditions, including epilepsy, neuropathic pain and generalised anxiety disorder. Similar to benzodiazepines,
More informationCSS Perspective - Opioid Risk Management
Tufts Health Care Institute Program on Opioid Risk Management Risk Evaluation and Mitigation Strategy for Prescription Opioids: An In-Depth Review of Fundamental Issues CSS Perspective - Opioid Risk Management
More informationThe Opioid Crisis Made in America Fade in America?
The Opioid Crisis Made in America Fade in America? The President s Commission On Combating Drug Addiction and the Opioid Crisis Bertha K Madras, PhD Professor of Psychobiology Department of Psychiatry
More informationOpioid Abuse and the Development of Abuse-Deterrent Drugs: Trends and Coverage in the Medicare Part D Program
Opioid Abuse and the Development of Abuse-Deterrent Drugs: Trends and Coverage in the Medicare Part D Program June 2015 Prepared by: Caroline F. Pearson, Craig Burton, Christine Harhaj, John A. Graziano
More informationClassification of Abuse-Related Events in Analgesic Clinical Trials: Recommendations and Research Agenda
Classification of Abuse-Related Events in Analgesic Clinical Trials: Recommendations and Research Agenda Nathaniel Katz, MD, MS Analgesic Research, Needham, MA Tufts University, Boston, MA IMMPACT XII,
More information2018 CPDD Meeting Wednesday, June 13 1:30 pm-1:45 pm (Pain Session)
2018 CPDD Meeting Wednesday, June 13 1:30 pm-1:45 pm (Pain Session) Assessment of Drug Abuse-Related Events with MADDERS in SUMMIT-07: A Phase-3 Study of NKTR-181 in Patients With Moderate to Severe Chronic
More informationCAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections
CAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections Dr. Fredrik Tiberg Assoc. Prof. President & CEO, Head R&D, Camurus Lund,
More informationThe Opioid Crisis among the Privately Insured
The Opioid Crisis among the Privately Insured The Opioid Abuse Epidemic as Documented in Private Claims Data A FAIR Health White Paper, July 2016 Copyright 2016, FAIR Health, Inc. Summary The United States
More informationEvaluating the Impact of Abuse Deterrent Formulations: Methodological Challenges in Postmarketing Data
Evaluating the Impact of Abuse Deterrent Formulations: Methodological Challenges in Postmarketing Data Judy A. Staffa, Ph.D., R.Ph. Associate Director for Public Health Initiatives Office of Surveillance
More informationAddressing Alaska s Opioid Epidemic From Understanding to Action
Addressing Alaska s Opioid Epidemic From Understanding to Action The opioid epidemic is devastating American families and communities. To curb these trends and save lives, we must help prevent addiction
More informationThe Use of Qualitative Research in Large Quantitative Studies: Capturing the Subtleties
The Use of Qualitative Research in Large Quantitative Studies: Capturing the Subtleties MARIA A. LEVI-MINZI, M.A., HILARY L. SURRATT, PH.D., STEVEN P. KURTZ, PH.D. THE QUALITATIVE REPORT 6 TH ANNUAL CONFERENCE
More informationTalking about SBIRT for adolescents: An upstream intervention to address the heroin and prescription opioid epidemic
Talking about SBIRT for adolescents: An upstream intervention to address the heroin and prescription opioid epidemic Brett R. Harris, DrPH University at Albany School of Public Health Drug Overdose is
More informationOpioids are effective medications available for the treatment of
original Article Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational
More informationBlueprint for Prescriber Continuing Education Program
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationTITLE: Tamper-Resistant Oxycodone: A Review of the Clinical Evidence and Costeffectiveness
TITLE: Tamper-Resistant Oxycodone: A Review of the Clinical Evidence and Costeffectiveness DATE: 25 June 2015 CONTEXT AND POLICY ISSUES Oxycodone is a prescription opioid used for chronic and acute pain
More informationNow available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet
Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE
More informationOpioid Crisis: How Did We Get Here & Where Are We Going? Amirala Pasha, DO, MS Assistant Professor of Medicine Division of General Internal Medicine
Opioid Crisis: How Did We Get Here & Where Are We Going? Amirala Pasha, DO, MS Assistant Professor of Medicine Division of General Internal Medicine Disclosures: None Disclaimer This presentation may contain
More informationDrug Evaluation. Paul Sloan 1, & Najib Babul 2 Author for correspondence: 1
Embeda : morphine sulfate extended-release capsules with sequestered naltrexone, a novel opioid formulation for the treatment of chronic pain Chronic opioids are often used in the management of chronic
More informationUPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY
UPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY Presented by Ii-Lun Chen, M.D Director Division of Individual Health Science Office of Science, CTP, FDA Disclaimer: This is not a formal dissemination
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationRevised European Guideline on PK and Clinical Evaluation of Modified Release Dosage Forms
1st MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis and Dissolution Jordan September 23 24, 2013 Revised European Guideline on PK and Clinical Evaluation of Modified Release Dosage
More informationMigraine: Developing Drugs for Acute Treatment Guidance for Industry
Migraine: Developing Drugs for Acute Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2018
More informationArticle #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic
Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention Understanding the Epidemic When the Prescription Becomes the Problem In a period of nine months, a tiny Kentucky county
More informationStrategies for Federal Agencies
Confronting Pain Management and the Opioid Epidemic Strategies for Federal Agencies Over the past 25 years, the United States has experienced a dramatic increase in deaths from opioid overdose, opioid
More informationOpioid Abuse: A Dark Tunnel
Opioid Abuse: A Dark Tunnel Sandra D. Comer, Ph.D. Professor of Neurobiology Division on Substance Abuse Department of Psychiatry Columbia University New York State Psychiatric Institute New York, NY Charles
More informationGuidance for Industry Migraine: Developing Drugs for Acute Treatment
Guidance for Industry Migraine: Developing Drugs for Acute Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationMorphaBond should be prescribed only by healthcare professionals who are knowledgeable in the use of opioids for the management of chronic pain.
PRESS RELEASE Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond Formulated with SentryBond Abuse-Deterrent Technology Parsippany, NJ and Basking
More informationA Pharmacist s Guide to the Emerging Abuse Deterrence Technology Used in Opioid Analgesics Louis Alexander, PhD, and Brianne Weingarten, MS
A Clinical Care Review FOR THE PHARMACIST This article sponsored by Purdue Pharma LP. A Pharmacist s Guide to the Emerging Abuse Deterrence Technology Used in Opioid Analgesics Louis Alexander, PhD, and
More informationAmyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry
Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationFDA s Response to the Opioid Crisis and the FDA Safe Use Initiative
FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative Scott K. Winiecki, MD Professional Affairs and Stakeholder Engagement Staff (PASES) Center For Drug Evaluation and Research (CDER) U.S.
More informationDsuvia (sufentanil) NEW PRODUCT SLIDESHOW
Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW Introduction Brand name: Dsuvia Generic name: Sufentanil Pharmacological class: Opioid agonist Strength and Formulation: 30mcg; sublingual tabs (housed in a disposable,
More informationOPIOID OVERDOSE EPIDEMIC: What Healthcare Providers Need to Know
OPIOID OVERDOSE EPIDEMIC: What Healthcare Providers Need to Know WHAT S NEW UPDATE CUMBERLAND, MD Renata J. Henry, M.Ed. Director, Central East ATTC March 16, 2016 Behavioral Health is Essential to Health
More information